Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALYACEN 1/35 vs GILDESS 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (Gn RH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
Prevention of pregnancy
Prevention of pregnancy,Treatment of moderate acne vulgaris,Contraceptive for women with menstrual disorders
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
No dosage adjustment required for mild-to-moderate renal impairment. Insufficient data for severe renal impairment; use with caution.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
GILDESS 1/20 (ethinyl estradiol 20 mcg/desogestrel 0.15 mg) is category X in pregnancy. First trimester: increased risk of congenital anomalies (e.g., heart defects, limb reduction) from estrogen component; cardiovascular and nervous system malformations reported. Second and third trimesters: associated with masculinization of female fetus from progestin; increased risk of IUGR and preterm birth. Use contraindicated in pregnancy.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
GILDESS 1/20 is a monophasic oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate. It is indicated for contraception and may be used for acne vulgaris in women at least 15 years old. Monitor for breakthrough bleeding, especially in the first cycles. Counsel patients to take at the same time daily to maintain efficacy. Caution in women with migraine with aura, hypertension, or history of thromboembolism. Prescribe as a 21-day regimen with a 7-day hormone-free interval.
No interactions on record
No interactions on record
ALYACEN 1/35 and GILDESS 1/20 are distinct pharmacological agents. ALYACEN 1/35 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancy. GILDESS 1/20 belongs to the Oral Contraceptive class and is primarily used for Prevention of pregnancyTreatment of moderate acne vulgarisContraceptive for women with menstrual disorders. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. ALYACEN 1/35 carries a safety status of Category C, whereas GILDESS 1/20 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Both ethinyl estradiol and gestodene are metabolized primarily in the liver via the cytochrome P450 3A4 (CYP3A4) pathway. Ethinyl estradiol undergoes first-pass metabolism and enterohepatic recirculation; gestodene is hydroxylated and conjugated.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Ethinylestradiol: 98% bound to albumin. Gestodene: 75-90% bound to sex hormone-binding globulin (SHBG) and albumin.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Ethinylestradiol: ~2.4 L/kg. Gestodene: ~0.7 L/kg. Indicates extensive tissue distribution.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
Oral: Ethinylestradiol ~40-60% (first-pass metabolism). Gestodene ~99% (highly bioavailable due to minimal first-pass effect).
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Contraindicated in hepatic adenomas, active liver disease, or Child-Pugh class B/C cirrhosis. For mild hepatic impairment (Child-Pugh A), no dosage adjustment; monitor.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in pediatric patients before menarche. Post-menarche, same as adult dosing; use only after establishment of regular menstrual cycles.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Not indicated for use in postmenopausal women. No specific geriatric dosing; generally not used in elderly women due to increased risk of thromboembolism.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is particularly pronounced in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
No specific food interactions are reported for GILDESS 1/20. However, grapefruit juice may increase estrogen levels; advise patients to consume grapefruit products in moderation. Alcohol may impair judgment regarding missed doses; recommend moderate intake.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Excreted in breast milk; ethinyl estradiol M/P ratio ~0.4, desogestrel M/P ratio ~0.6. May reduce milk quantity and quality; small amounts pose theoretical risk of estrogenic effects in infant. Generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
No dose adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased hepatic metabolism, increased renal clearance) would reduce efficacy, but use is not recommended.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
Take one pill at the same time every day, even if you do not have sex often.,If you miss a pill, follow the instructions in the package insert or consult your healthcare provider.,Use a backup method (like condoms) if you miss more than one pill or start late.,Common side effects include nausea, breast tenderness, and spotting, especially in the first few cycles.,Contact your doctor if you experience severe abdominal pain, chest pain, headache, vision changes, or leg pain/swelling.,Smoking increases the risk of serious cardiovascular side effects; avoid smoking while on this medication.,Do not take GILDESS if you are pregnant or suspect pregnancy.